logo-loader
viewe-Therapeutics PLC

e-Therapeutics continuing to convert business development into cash generating partnerships

e-Therapeutics PLC's (LON:ETX) Ray Barlow says they're actively engaged in exploring all organic and non-organic opportunities that have the potential to create incremental value for its shareholders.

He adds that multiple proposals for its artificial intelligence-based drug research products have been sent to potential partners and customers.

Quick facts: e-Therapeutics PLC

Price: 8.8 GBX

AIM:ETX
Market: AIM
Market Cap: £28.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

e-Therapeutics PLC using its drug discovery platform in search for COVID-19...

e-therapeutics PLC's (LON:ETX) CTO Jonny Wray talks Proactive London's Andrew Scott through their drug discovery platform, the work they've done to date and what they're doing currently to help find effective antivirals against coronavirus. The firm's computer simulation platform has...

1 week, 4 days ago

2 min read